Hydroxyurea (hydroxycarbamide) for sickle cell disease-Reference-Cited by-同舟云学术

Hydroxyurea (hydroxycarbamide) for sickle cell disease

Published:2022-09-01 Issue:10 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Rankine-Mullings Angela E¹,Nevitt Sarah J²

Affiliation:

1. Sickle Cell Unit; Caribbean Institute for Health Research, University of the West Indies; Kingston Jamaica

2. Department of Health Data Science; University of Liverpool; Liverpool UK

Publisher

Wiley

Subject

Pharmacology (medical)

Reference291 articles.

1. TCD in infants: a report from the BABY HUG trial;Adams;Blood,2005

2. Adams RJ Luden J Miller S Wang W Rees R Li D TCD in infants: a report from the Baby Hug study 28th Annual Meeting of the National Sickle Cell Disease Program; 2005 Apr 9-13; Cincinnati, Ohio 2005 105

3. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia;Alvarez;Pediatric Blood & Cancer,2012

4. Developmental function in toddlers with sickle cell anemia;Armstrong;Pediatrics,2013

5. Neurodevelopment in infants with sickle cell anemia: baseline data from the Baby HUG trial;Armstrong;Blood,2008

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Review on Hydroxyurea Usage in Young Children with Sickle Cell Disease: Examining Hemoglobin Induction, Potential Benefits, Responses, Safety, and Effectiveness;International Journal of Clinical Medicine;2024

2. Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing;American Journal of Hematology;2023-11-27

3. Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling;Nature Communications;2023-09-20

4. The Effectiveness of Common Interventions in the Management of Sickle Cell Disease in Primary Care Settings: A Review;Cureus;2023-09-06

5. CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease;New England Journal of Medicine;2023-08-31